Gelteq (GELS) Stock Price, News & Analysis

Company Overview

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Key Stats

• Today's Range: $0.58 to $0.62
• 50-Day Range: $0.39 to $1.53
• 52-Week Range: $0.39 to $2.02
• Volume: 193,535 shs
• Average Volume: 95,411 shs
• Market Capitalization: $6.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Gelteq Stock Analysis - MarketRank™

Gelteq scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Gelteq has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Gelteq has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Gelteq has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.56% of the float of Gelteq has been sold short.

Short Interest Ratio / Days to Cover

Gelteq has a short interest ratio ("days to cover") of 0.37, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gelteq has recently decreased by 60.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gelteq does not currently pay a dividend.

Dividend Growth

Gelteq does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for GELS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gelteq insiders have not sold or bought any company stock.

Percentage Held by Institutions

Gelteq has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 7/21/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GELS
• Previous Symbol: NASDAQ:GELS
• CIK: 1920092
• Web: www.gelteq.com
• Phone: 61-3-9087-3990
• Fax: N/A
• Employees: N/A
• Year Founded: 2018

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $165.65 thousand
• Price / Sales: 39.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.08 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 10,711,000
• Free Float: N/A
• Market Cap: $6.53 million
• Optionable: N/A
• Beta: -0.55